Page 1

inventiva PRESS RELEASE Inventiva reports first quarter 2021 financial information¹ and updates on the collaboration with AbbVie in auto - immune diseases Cash and cash equivalents at € 107.8m as of March 31 , 2021 Revenues of € 0.1m in Q1 2021 Decision by AbbVie to move into Phase llb clinical development with cedirogant in psoriasis , following promising results in its Phase lb clinical trial Daix ( France ) , May 12 , 2021 - Inventiva ( Euronext Paris and Nasdaq : IVA ) , a clinical - stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non - alcoholic steatohepatitis ( NASH ) , mucopolysaccharidoses ( MPS ) and other diseases with significant unmet medical need , today reported its cash position as of March 31 , 2021 and its revenues for the first quarter of 2021 , and provided an update on its collaboration with AbbVie in auto - immune diseases . Cash Position As of March 31 , 2021 , Inventiva's cash and cash equivalents stood at € 107.8 million compared to € 113.0 million as of December 31 , 2020 . Net cash used in operating activities amounted to € 7.8 million in the first quarter of 2021 compared to € 3.6 million for the same period in 2020. R & D expenses for the first quarter , mainly driven by the development of lanifibranor in NASH , were up 22 % compared to the first quarter of 2020. This increase in cash used is due to the preparation for the initiation of NATIV3 , a Phase III clinical trial evaluating lanifibranor in NASH , while the first quarter of 2020 had been positively impacted by the receipt of a € 4.2 million non - recurrent late payment of the 2018 research tax credit . Net cash from investing activities for the first quarter of 2021 amounted to € 1.1 million , as compared to no net cash from investing activities generated in the first quarter of 2020 . No net cash from financing activities was generated over the first quarter of 2021 while Inventiva recorded € 14.6 million of net cash from financing activities for the same period in 2020 , notably related to the issuance of € 15 million ( gross proceeds ) of ordinary shares in February 2020 . Over the first quarter of 2021 , the Company recorded a positive exchange rate effect on cash and cash equivalent of € 3.7 million . Considering its current R & D and clinical development programs , and excluding additional financial resources , Inventiva has adjusted its projected cash runway by one quarter , allowing the Company to finance its operating activities through the third quarter of 2022 compared to the fourth quarter of 2022 as previously communicated . 1 Non - audited financial information . 1